Adult Stem Cell Study Demonstrates Improved Quality of Life for Patients Suffering from Spinal Cord Injury

LOS ANGELES--(BUSINESS WIRE)--DaVinci Biosciences announced today the publication of study results demonstrating the safety and feasibility of its acute and chronic spinal cord injury therapy platform in issue 17(12) of Cell Transplantation, a peer-reviewed journal focused on regenerative medicine. The study demonstrates that administering adult autologous bone marrow derived stem cells via multiple routes is feasible, safe, and most importantly, improves the quality of life for both acute and chronic spinal cord injury (SCI) patients.

“While this was only a safety and feasibility study, the outcome for our patients was amazing and we plan to build upon our results”

The study documents the first eight of 52 patients (four acute and four chronic) who were administered autologous bone marrow derived stem cells using a multiple route delivery technique. A two-year follow-up was performed on these first eight patients. Using sequential MRIs, the follow-up demonstrated noticeable morphological changes within the spinal cord after administration of autologous stem cells. Participating spinal cord injury patients experienced varying degrees of improvement in their quality of life, such as increased bladder control, regained mobility and sensation. Most importantly, the study demonstrated no adverse effects such as tumor formation, increased pain, and/or deterioration of function following administration of autologous stem cells. In a video provided by the Luis Vernaza Hospital, patients involved in the study can be seen discussing their improved quality of life at: http://bit.ly/DavinciStemCellStudy. For more information on the study or to read the published article, visit www.davincibiosciences.com.

“While this was only a safety and feasibility study, the outcome for our patients was amazing and we plan to build upon our results,” said Francisco Silva, President of DaVinci Biosciences.

About DaVinci Biosciences

DaVinci Biosciences LLC is a privately held company dedicated to advancing therapies that improve the quality of life for individuals suffering from trauma, disease and degenerative disorders. Through independent research and partnerships with universities, medical research institutions, and hospitals, DaVinci Biosciences continues to discover biological breakthroughs relating to and further improving the treatment of degenerative disorders and injury. DaVinci Biosciences is headquartered in Costa Mesa, California. For more information please visit www.davincibiosciences.com.